Tue, Sep 2, 2014, 11:25 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Vertex Pharmaceuticals Incorporated Message Board

  • stockhero@rocketmail.com stockhero Nov 1, 2012 7:08 AM Flag

    HEB (Price: 0.79) = FDA APPROVAL WITHIN 2 MONTHS= $7++COMING=RALLYYYYYYYYYYYYYYYYYYYYYYYYYYY

     

    This Goldmine has BRUTAL upside potential because Ampligen will be the first Drug which could get approval for Chronic Fatigue Syndrome .
    There are 4 Million CFS (Chronic Fatigue Syndrome) Patients in USA alone a treatment with Ampligen will cost between $30000-50000 means the Drug has MULTI BILLION DOLLAR POTENTIAL .

    You can play the Runup to Decision if you dont like to hold trough the decision Its a win win situation from current bargain level . Heb could run to $3 before ADCOM meeting like in 2009 .

    My Target is $2-3 before Decision and $7++ after FDA approval . GLTA

    Hemispherx (HEB)

    MarketCap : $120 M
    Cash : $38 M

    Price: $0.79

    Hemispherx Biopharma Announces FDA Confirms Advisory Committee Meeting on December 20, 2012
    Arthritis Advisory Committee Will Review Ampligen(R) for Chronic Fatigue Syndrome

    PHILADELPHIA, Oct. 22, 2012 -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) today announced that the U.S. Food and Drug Administration ("FDA") has scheduled for December 20, 2012 a meeting of the Arthritis Advisory Committee ("AAC") to discuss the Ampligen(R) New Drug Application for Chronic Fatigue Syndrome ("CFS") which is currently under review by the FDA. As previously announced, the Prescription Drug User Fee Act ("PDUFA") review goal for the FDA to complete its review is February 2, 2013.

    ..................................

    This topic is deleted.
 
VRTX
92.96-0.61(-0.65%)Sep 2 4:15 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.